title: Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer.
abstract: BACKGROUND
  Early detection is essential to improve the outcome of patients with pancreatic cancer. A noninvasive and cost-effective diagnostic test using plasma/serum biomarkers would facilitate the detection of pancreatic cancer at the early stage.
  
  
  METHODS
  Using a novel combination of hollow fiber membrane-based low-molecular-weight protein enrichment and LC-MS-based quantitative shotgun proteomics, we compared the plasma proteome between 24 patients with pancreatic cancer and 21 healthy controls (training cohort). An identified biomarker candidate was then subjected to a large blinded independent validation (n = 237, validation cohort) using a high-density reverse-phase protein microarray.
  
  
  RESULTS
  Among a total of 53,009 MS peaks, we identified a peptide derived from CXC chemokine ligand 7 (CXCL7) that was significantly reduced in pancreatic cancer patients, showing an area under curve (AUC) value of 0.84 and a P value of 0.00005 (Mann-Whitney U test). Reduction of the CXCL7 protein was consistently observed in pancreatic cancer patients including those with stage I and II disease in the validation cohort (P < 0.0001). The plasma level of CXCL7 was independent from that of CA19-9 (Pearson's r = 0.289), and combination with CXCL7 significantly improved the AUC value of CA19-9 to 0.961 (P = 0.002).
  
  
  CONCLUSIONS
  We identified a significant decrease of the plasma CXCL7 level in patients with pancreatic cancer, and combination of CA19-9 with CXCL7 improved the discriminatory power of the former for pancreatic cancer.
  
  
  CONCLUSIONS
  The present findings may provide a new diagnostic option for pancreatic cancer and facilitate early detection of the disease.
authors.affiliation: Chemotherapy Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
authors.forename: Junichi
authors.initials: J
authors.lastname: Matsubara
authors.forename: Kazufumi
authors.initials: K
authors.lastname: Honda
authors.forename: Masaya
authors.initials: M
authors.lastname: Ono
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Michimoto
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Giman
authors.initials: G
authors.lastname: Jung
authors.forename: Koji
authors.initials: K
authors.lastname: Yanagisawa
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Sakuma
authors.forename: Shoji
authors.initials: S
authors.lastname: Nakamori
authors.forename: Naohiro
authors.initials: N
authors.lastname: Sata
authors.forename: Hideo
authors.initials: H
authors.lastname: Nagai
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Ioka
authors.forename: Takuji
authors.initials: T
authors.lastname: Okusaka
authors.forename: Tomoo
authors.initials: T
authors.lastname: Kosuge
authors.forename: Akihiko
authors.initials: A
authors.lastname: Tsuchida
authors.forename: Masashi
authors.initials: M
authors.lastname: Shimahara
authors.forename: Yohichi
authors.initials: Y
authors.lastname: Yasunami
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Chiba
authors.forename: Setsuo
authors.initials: S
authors.lastname: Hirohashi
authors.forename: Tesshi
authors.initials: T
authors.lastname: Yamada
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood; D016022:Case-Control Studies; D002853:Chromatography, Liquid; D005260:Female; D006801:Humans; D008297:Male; D013058:Mass Spectrometry; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000175:diagnosis; D011446:Prospective Studies; D015203:Reproducibility of Results; D001620:beta-Thromboglobulin / Q000032:analysis / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; C061615:PPBP protein, human; D001620:beta-Thromboglobulin